Javelin Biotech Technology Powering New Non-Animal Testing Initiative at UConn School of Pharmacy
Javelin Biotech is proud to announce its central role in a new initiative at the University of Connecticut School of Pharmacy aimed at advancing alternatives to animal testing. Seeded by a $250,000 gift from pharmaceutical pioneer and Javelin board member Jane Hirsh ’65 (PHARM), the program establishes the Jane Hirsh Fellowship and the Hirsh Fund for Non-Animal Testing Innovation.
As a cornerstone of this initiative, UConn will integrate Javelin Biotech’s state-of-the-art organ-on-a-chip technology into its research and graduate curriculum. This partnership allows students and researchers to work directly with our human-centric platforms, which provide more predictive and ethical data for drug development than traditional animal models.
“As biomedical science continues to evolve, it is important that education evolves with it,” says Hirsh. “This initiative is intended to help prepare students to work with modern, human-relevant technologies that can make drug development more effective, more responsible, and ultimately more impactful for patients.”
The collaboration comes at a pivotal moment in the industry. With the passage of the FDA Modernization Act 3.0, regulatory bodies are increasingly embracing New Approach Methodologies (NAMs) to replace, reduce, or refine animal testing. Javelin Biotech is at the forefront of this movement, ensuring that the pharmaceutical workforce of tomorrow is equipped with the tools necessary to meet these new standards.